The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. RESULTS: During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib). CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
In the citing paper
“both the rarity of co-drivers and strong addiction to the ALK fusion oncoprotein may account for the long progression-free survival observed in patients with ALK-rearrangements with the potent and selective second and third generation ALK inhibitors alectinib, brigatinib and lorlatinib23, 26, 27.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citationGainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A., West, H., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 709
Self-citationShaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citationOu, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 592
Self-citationBrain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 265
Self-citationALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 245
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Awad MM, 2014, Clin Adv Hematol Oncol, 12, 429
- Lu S, 2016, J Clin Oncol
- Hida T, Lancet
Cited by
Sorted by citations
Items 601–700 of 1,000
Inferring Cell-type-specific Genes of Lung Cancer Based on Deep Learning
Huang, J., Cheng, N., Chen, C., & Li, C. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220324110914 · Cited by 28
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer
Pruis, M. A., Veerman, G., Hassing, H. C., Lanser, D. A. C., Paats, M. S., van Schaik, R. H. N., Mathijssen, R. H. J., Manintveld, O. C., & Dingemans, A. C. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.006 · Cited by 28
Advancements of ALK inhibition of non-small cell lung cancer: a literature review
Zia, V. A. D. A., Lengyel, C. G., Tajima, C. C., & de Mello, R. A. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-619 · Cited by 28
Polcaro, G., Liguori, L., Manzo, V., Chianese, A., Donadio, G., Caputo, A., Scognamiglio, G., Dell’Annunziata, F., Langella, M., Corbi, G., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01976-2 · Cited by 29
Beardslee, T. J., & Lawson, J. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.1.8 · Cited by 28
Ramachandran, P. V., Morcus, R., Tahir, M. I., Onukogu, I. D., Spinowitz, B., & Wang, J. C. C. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-018-1849-y · Cited by 28
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
Gavralidis, A., & Gainor, J. F. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000491 · Cited by 28
Li, Y., Ye, J., Xu, S., & Wang, J. (2023) · Discover Oncology · doi:10.1007/s12672-023-00686-3 · Cited by 27
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
Ricciuti, B., Giglio, A. D., Mecca, C., Arcuri, C., Marini, S., Metro, G., Baglivo, S., Sidoni, A., Bellezza, G., Crinò, L., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1133-4 · Cited by 27
Ali, R. A., Arshad, J., Palacio, S., & Mudad, R. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s147499 · Cited by 27
Li, H., Lai, L., & Wu, B. Y. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00880-8 · Cited by 27
The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
Liu, S., Huang, T., Liu, M., He, W., Zhao, Y., Yang, L., Long, Y., Zong, D., Zeng, H., Liu, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00726 · Cited by 27
Targeted Therapy for Non-Small Cell Lung Cancer
Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
Remón, J., Besse, B., Leary, A. F., Bièche, I., Job, B., Lacroix, L., Auguste, A., Mauduit, M., Audigier-Valette, C., Raimbourg, J., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100068 · Cited by 28
de Salins, V., Loganadane, G., Joly, C., Abulizi, M., Nourieh, M., Boussion, H., Belkacémi, Y., Tournigand, C., & Kempf, E. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i7.495 · Cited by 27
Stencel, K. M., Chmielewska, I., Milanowski, J., & Ramlau, R. (2021) · Cancers · doi:10.3390/cancers13081829 · Cited by 27
Sánchez‐Herrero, E., Serna‐Blasco, R., Ivanchuk, V., García‐Campelo, R., Gómez, M. D., Sánchez, J. M., Massutí, B., Reguart, N., Camps, C., Sanz‐Moreno, S., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13033 · Cited by 27
Zhao, B., Han, Y., Wang, Y., Wang, Y., Wang, Y., Xing, H., Dai, C., Wang, Y., Wang, H., & Ma, W. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105931 · Cited by 27
Lin, J. J., Muzikansky, A., Kennedy, E., Kuberski, H., Stober, L. L., Wanat, A. C., Azzoli, C. G., Lennes, I. T., Sequist, L. V. D., Dagogo‐Jack, I., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100342 · Cited by 27
Self-citationSun, S. A., Pithavala, Y. K., Martini, J., & Chen, J. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2056 · Cited by 28
Importance of ROS1 fene fusions in non-small cell lung cancer
Muminovic, M., Uribe, C. R. C., Alvarez-Pinzon, A. M., Shan, K. S., & Raez, L. E. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.105 · Cited by 28
Sisi, M., Fusaroli, M., Giglio, A. D., Facchinetti, F., Ardizzoni, A., Raschi, E., & Gelsomino, F. (2022) · Targeted Oncology · doi:10.1007/s11523-021-00865-8 · Cited by 27
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Mina, S. A., Shanshal, M., Leventakos, K., & Parikh, K. (2025) · Cancers · doi:10.3390/cancers17030353 · Cited by 27
Anaemia in cancer patients: Advances and challenges in the era of precision oncology
Miglietta, F., Pirozzi, M., Bottosso, M., Pisani, C., Franco, P., Guarneri, V., & Gennari, A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104788 · Cited by 27
Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma
Heath, J. A., Campbell, M., Thomas, A., & Solomon, B. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27055 · Cited by 26
Mason, C., Ellis, P. G., Lokay, K., Barry, A., Dickson, N. R., Page, R. D., Polite, B. N., Salgia, R., Savin, M., Shamah, C. J., et al. (2018) · Journal of Clinical Pathways · doi:10.25270/jcp.2018.02.00001 · Cited by 26
Karim, N. A., & Kelly, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0112 · Cited by 26
Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
Maung, T. Z., Ergin, H. E., Javed, M., Inga, E. E., & Khan, S. (2020) · Cureus · doi:10.7759/cureus.8095 · Cited by 26
Kamer, I., Steuerman, Y., Daniel‐Meshulam, I., Perry, G., Izraeli, S., Perelman, M., Golan, N., Simansky, D. A., Barshack, I., Nun, A. B., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-477 · Cited by 26
PRDX2 Promotes the Proliferation and Metastasis of Non‐Small Cell Lung Cancer In Vitro and In Vivo
Chen, Y., Yang, S., Zhou, H., & Su, D. (2020) · BioMed Research International · doi:10.1155/2020/8359860 · Cited by 26
Luca, C. D., Pepe, F., Iaccarino, A., Pisapia, P., Righi, L., Listì, A., Greco, L., Gragnano, G., Campione, S., Dominicis, G. D., et al. (2021) · Cancers · doi:10.3390/cancers13010139 · Cited by 26
Self-citationTargeting TRK: A fast-tracked application of precision oncology and future directions
Kojadinovic, A., Laderian, B., & Mundi, P. S. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103451 · Cited by 26
Jünger, S. T., Reinecke, D., Meißner, A.-K., Goldbrunner, R., & Grau, S. (2021) · Journal of neurosurgery · doi:10.3171/2021.7.jns211172 · Cited by 27
Baldacci, S., Besse, B., Avrillon, V., Mennecier, B., Mazières, J., Dubray‐Longeras, P., Cortot, A. B., Descourt, R., Doubre, H., Quantin, X., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.018 · Cited by 27
Rodon, J. A., Gray, N. S., Mok, T. S. K., & Gainor, J. F. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_242209 · Cited by 27
Self-citationGenova, C., Rossi, G., Tagliamento, M., Rijavec, E., Biello, F., Cerbone, L., Zullo, L., & Grossi, F. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1714441 · Cited by 27
Kovalchuk, B., Berghoff, A. S., Karreman, M. A., Frey, K., Piechutta, M., Fischer, M. D., Grosch, J. K., Heiland, S., Breckwoldt, M. O., Hilberg, F., et al. (2020) · Clinical & Experimental Metastasis · doi:10.1007/s10585-020-10055-x · Cited by 27
Su, C., Jiang, Y., Jiang, W. I., Wang, H., Liu, S., Shao, Y. W., Zhao, W., Ning, R., & Yu, Q. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s282933 · Cited by 26
Kraft, J., Mayinger, M. C., Willmann, J., Brown, M. L. H., Tanadini‐Lang, S., Wilke, L., Gückenberger, M., & Andratschke, N. H. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03714-w · Cited by 26
Zhao, M., Shao, T., Shao, H., Zhou, C., & Tang, W. (2024) · BMC Cancer · doi:10.1186/s12885-024-11916-4 · Cited by 26
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Ye, W., Lu, X., Qiao, Y., & Ou, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189108 · Cited by 26
Chang, A. E. B., Piper-Valillo, A. J., Mak, R. H., Lanuti, M. D., Muzikansky, A., Rotow, J. K., Janne, P. A., Mino-Kenudson, M. A., Swanson, S., Wright, C. D., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae107 · Cited by 25
Alsaed, B., Bobik, N., Laitinen, H. K., Nandikonda, T., Ilonen, I., & Haikala, H. M. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10272-4 · Cited by 25
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
Barrows, S., Wright, K. R., Copley‐Merriman, C., Kaye, J. A., Chioda, M. D., Wiltshire, R., Torgersen, K. M., & Masters, E. T. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s179349 · Cited by 26
Rajurkar, S. P., Mambetsariev, I., Pharaon, R. R., Leach, B., Tan, T., Kulkarni, P., & Salgia, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061870 · Cited by 25
Myall, N. J., Lei, A. Q., & Wakelee, H. A. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-564 · Cited by 25
Carcereny, E., Fernández-Nistal, A., López, A., Montoto, C., Naves, A., Segú-Vergés, C., Coma, M., Jorba, G., Oliva, B., & Mas, J. M. (2021) · Oncotarget · doi:10.18632/oncotarget.27875 · Cited by 25
Li, M., An, Z., Tang, Q., Ma, Y., Yan, J., Chen, S., & Wang, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16897 · Cited by 25
Systemic Therapy for Lung Cancer Brain Metastases
Pellerino, A., Bruno, F., Rudà, R., & Soffietti, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00911-7 · Cited by 26
Nadler, E., Vasudevan, A., Wang, Y., & Ogale, S. S. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100522 · Cited by 25
Geng, D., Guo, Q., Huang, S., Zhang, H., Guo, S., & Li, X. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221078429 · Cited by 25
Schmid, S., Cheng, S., Chotai, S., García-Pardo, M., Zhan, L. J., Hueniken, K., Balaratnam, K., Khan, K., Patel, D., Grant, B., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.09.007 · Cited by 25
Targeted therapy of RET fusion-positive non-small cell lung cancer
Shen, Z., Qiu, B., Li, L., Yang, B., & Guang-hu, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1033484 · Cited by 25
Fan, J., Xia, Z., Zhang, X., Chen, Y., Qian, R., Liu, S., You, D., Zhang, J., & Luo, P. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s156170 · Cited by 25
Okimoto, T., Tsubata, Y., Hotta, T., Hamaguchi, M., Nakao, M., Hamaguchi, S., Hamada, A., & Isobe, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1072-18 · Cited by 25
Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer
Yang, J., & Gong, W.-L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1570846 · Cited by 25
Batra, U., Sharma, M., Amrith, B. P., Mehta, A., & Jain, P. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.016 · Cited by 25
Singh, A., & Chen, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s260274 · Cited by 25
Gadgeel, S. M., Shaw, A. T., Barlési, F., Crinò, L., Yang, J. C., Dingemans, A. C., Kim, D., de Marinis, F., Schulz, M., Liu, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.395 · Cited by 25
Self-citationDormieux, A., Mezquita, L., Cournède, P.-H., Remón, J., Tazdait, M., Lacroix, L., Rouleau, É., Adam, J., Bluthgen, M. V., Facchinetti, F., et al. (2020) · European Radiology · doi:10.1007/s00330-020-06784-y · Cited by 24
The Role of Stereotactic Biopsy in Brain Metastases
Yu, K. K. H., Patel, A., & Moss, N. S. (2020) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2020.06.002 · Cited by 26
Haratake, N., Toyokawa, G., Seto, T., Tagawa, T., Okamoto, T., Yamazaki, K., Takeo, S., & Mori, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1940964 · Cited by 24
Rubino, S., Oliver, D. E., Tran, N., Vogelbaum, M. A., Forsyth, P. A., Yu, H.-H. M., Ahmed, K. A., & Etame, A. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.854402 · Cited by 24
Novel targeted therapies for advanced non-small lung cancer
Abughanimeh, O. K. M., Kaur, A., Osta, B. E. E., & Ganti, A. K. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.03.003 · Cited by 26
Koster, K., Appenzeller, C., Lauber, A., Früh, M., & Schmid, S. (2022) · Case Reports in Oncology · doi:10.1159/000525341 · Cited by 24
Vaishnavi, A., Juan, J. M., Jacob, M., Stehn, C. M., Gardner, E. E., Scherzer, M. T., Schuman, S. S., van Veen, J. E., Murphy, B., Hackett, C. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3214 · Cited by 24
Albaba, H., Lim, C. H., & Leighl, N. B. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0563-8 · Cited by 24
Le‐Rademacher, J. G., Dahlberg, S. E., Lee, J. J., Adjei, A. A., & Mandrekar, S. J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2019 · Cited by 24
Treatment of older patients with advanced non-small cell lung cancer: A challenge
Decoster, L., & Schallier, D. C. C. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.09.008 · Cited by 24
Combinations using checkpoint blockade to overcome resistance
Morganti, S., & Curigliano, G. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1148 · Cited by 25
Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials
Yu, L., Yang, R., Long, Z., Tao, Q., & Liu, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1451230 · Cited by 23
Koyama, J., Morise, M., Furukawa, T., Oyama, S., Matsuzawa, R., Tanaka, I., Wakahara, K., Yokota, H., Kimura, T., Shiratori, Y., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-13190-w · Cited by 25
Lucia, A. D., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crinò, L., de Souza, P. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515748 · Cited by 25
Li, J., Knoll, S., Bocharova, I., Tang, W., & Signorovitch, J. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541443 · Cited by 23
Liu, M., Zhang, L., Huang, Q., Li, N., Zheng, B., & Cai, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s223441 · Cited by 23
Peng, Y., Zhao, Q., Liao, Z., Ma, Y., & Ma, D. (2023) · Cancer · doi:10.1002/cncr.34664 · Cited by 23
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types
Schubert, L., Elliott, A., Le, A. T., Estrada‐Bernal, A., Doebele, R. C., Lou, E., Borghaei, H., Demeure, M. J., Kurzrock, R., Reuss, J. E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1115405 · Cited by 23
Self-citationZhou, Q. H., Zhao, J., Chang, J., Wang, H., Fan, Y., Wang, K., Wu, G., Nian, W., Sun, Y., Sun, M., et al. (2023) · Cancer · doi:10.1002/cncr.34897 · Cited by 23
Bhandari, N. R., Hess, L. M., He, D., & Peterson, P. M. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7039 · Cited by 23
Deep learning ensembles for detecting brain metastases in longitudinal multi-modal MRI studies
Machura, B., Kucharski, D., Bożek, O., Eksner, B., Kokoszka, B., Pekala, T., Radom, M., Strzelczak, M., Zarudzki, Ł., Gutiérrez-Becker, B., et al. (2024) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2024.102401 · Cited by 23
Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues
Wu, X., Zhu, L., & Ma, P. C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199767 · Cited by 23
Sakakibara‐Konishi, J., Kitai, H., Ikezawa, Y., Hatanaka, Y., Sasaki, T., Yoshida, R., Chiba, S., Matsumoto, S., Goto, K., Mizugaki, H., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.021 · Cited by 23
Patel, A. K., Batra, U., Prasad, K. T., Dabkara, D., Ghosh, J., Sharma, M., Singh, N., Suresh, P., Jain, P., Malik, P. S., et al. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100571 · Cited by 23
Xia, B., Nagasaka, M., Zhu, V. W., Ou, S. I., & Soo, R. A. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-331 · Cited by 24
Self-citationGower, A., Golestany, B., Gong, J., Singhi, A. D., & Hendifar, A. E. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00365 · Cited by 23
Engineering Multidimensional Evolutionary Forces to Combat Cancer
McCoach, C. E., & Bivona, T. G. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1196 · Cited by 23
Goto, Y., Yamamoto, N., Masters, E. T., Kikkawa, H., Mardekian, J., Wiltshire, R., Togo, K., & Ohe, Y. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01392-0 · Cited by 22
Stegherr, R., Schmoor, C., Beyersmann, J., Rufibach, K., Jehl, V., Brückner, A., Eisele, L., Künzel, T., Kupas, K., Langer, F., et al. (2021) · Trials · doi:10.1186/s13063-021-05354-x · Cited by 22
Chow, R., Lage, D. E., Williams, G. R., Sedrak, M. S., Greer, J. A., Temel, J. S., & Nipp, R. D. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7055 · Cited by 22
Ou, S. I., Lee, A. T., & Nagasaka, M. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104019 · Cited by 22
Self-citationQin, A., & Gadgeel, S. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0526-1 · Cited by 22
Self-citationLiu, Z., Jiang, L., Li, Y., Xie, B., Xie, J., Wang, Z., Zhou, X., Jiang, H., Fang, Y., Pan, H., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.019 · Cited by 22
Guan, H., Sheng, Y., Guo, W., Han, S., & Shi, L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00908-7 · Cited by 22
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
Facchinetti, F., & Friboulet, L. (2019) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s190786 · Cited by 23
Wang, W., Sun, X. S., & Hui, Z. (2019) · Oncology Research and Treatment · doi:10.1159/000502755 · Cited by 22
Liu, C., Yu, H., Long, Q., Chen, H., Li, Y., Zhao, W., Zhao, K., Zhu, Z., Sun, S., Fan, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01116 · Cited by 22
Sheinson, D. M., Wong, W. B., Wu, N., & Mansfield, A. S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.005 · Cited by 22
Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer
the Israel Lung Cancer Group, Dudnik, E., Agbarya, A., Grinberg, R., Cyjon, A., Bar, J., Moskovitz, M. T., & Peled, N. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02376-w · Cited by 22
Darsa, H. E., Abdel-Rahman, O. M., & Sangha, R. S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774552 · Cited by 22
Gibson, A. J. W., Box, A. H., Dean, M. L., Elegbede, A. A., Hao, D., Sangha, R. S., & Bebb, D. G. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100157 · Cited by 22
Metadata
- Authors
- Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 829-838
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2624310346
- Cited by
- 2,527
- References
- 14
- Citations by year
- 2026: 173 · 2025: 216 · 2024: 260 · 2023: 270 · 2022: 306 · 2021: 336 · 2020: 327 · 2019: 276 · 2018: 277 · 2017: 82
- FWCI
- 218.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, public-domain)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Ariad Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Array BioPharma
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Les Laboratories Pierre Fabre
- Clovis Oncology
- G1 Therapeutics
- Eisai
- Genentech
- EMD Serono
- Ignyta
- Loxo Oncology
- Foundation Medicine
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- alectinib, crizotinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, ALK inhibitors, progression-free survival, CNS progression, central nervous system metastasis, objective response rate, overall survival, first-line therapy, targeted therapy, head-to-head comparison
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Adult, Aged, 80 and over, Animals, Antineoplastic Agents, Carbazoles, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Piperidines, Pyrazoles, Pyridines, Central Nervous System Neoplasms, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
